FR14C0033I2 - Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine - Google Patents

Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine

Info

Publication number
FR14C0033I2
FR14C0033I2 FR14C0033C FR14C0033C FR14C0033I2 FR 14C0033 I2 FR14C0033 I2 FR 14C0033I2 FR 14C0033 C FR14C0033 C FR 14C0033C FR 14C0033 C FR14C0033 C FR 14C0033C FR 14C0033 I2 FR14C0033 I2 FR 14C0033I2
Authority
FR
France
Prior art keywords
phenyl
serotonin reuptake
reuptake inhibitors
piperazine derivatives
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0033C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of FR14C0033I1 publication Critical patent/FR14C0033I1/fr
Application granted granted Critical
Publication of FR14C0033I2 publication Critical patent/FR14C0033I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
FR14C0033C 2001-10-04 2014-04-16 Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine Active FR14C0033I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04
PCT/DK2002/000659 WO2003029232A1 (en) 2001-10-04 2002-10-02 Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Publications (2)

Publication Number Publication Date
FR14C0033I1 FR14C0033I1 (OSRAM) 2014-06-13
FR14C0033I2 true FR14C0033I2 (fr) 2014-11-14

Family

ID=8160750

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0033C Active FR14C0033I2 (fr) 2001-10-04 2014-04-16 Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine

Country Status (38)

Country Link
US (10) US7144884B2 (OSRAM)
EP (2) EP1436271B3 (OSRAM)
JP (3) JP3896116B2 (OSRAM)
KR (3) KR100770194B1 (OSRAM)
CN (1) CN1319958C (OSRAM)
AR (2) AR036659A1 (OSRAM)
AT (2) ATE441631T1 (OSRAM)
AU (2) AU2002333220C1 (OSRAM)
BE (1) BE2014C036I2 (OSRAM)
BR (3) BR122012009534C8 (OSRAM)
CA (1) CA2462110C (OSRAM)
CO (1) CO5580746A2 (OSRAM)
CY (3) CY1107924T1 (OSRAM)
DE (2) DE60225162T3 (OSRAM)
DK (2) DK1749818T3 (OSRAM)
EA (2) EA011096B1 (OSRAM)
EG (1) EG25095A (OSRAM)
ES (2) ES2298425T7 (OSRAM)
FR (1) FR14C0033I2 (OSRAM)
HR (1) HRP20040220A2 (OSRAM)
HU (3) HU230189B1 (OSRAM)
IL (1) IL160655A0 (OSRAM)
IS (2) IS2578B (OSRAM)
LT (1) LTC1436271I2 (OSRAM)
LU (1) LU92397I2 (OSRAM)
ME (1) ME00039B (OSRAM)
MX (1) MXPA04002959A (OSRAM)
MY (1) MY140950A (OSRAM)
NL (1) NL300652I1 (OSRAM)
NO (3) NO326443B1 (OSRAM)
NZ (1) NZ531556A (OSRAM)
PL (2) PL209253B1 (OSRAM)
PT (2) PT1749818E (OSRAM)
RS (2) RS52865B (OSRAM)
SI (1) SI1436271T1 (OSRAM)
UA (2) UA81749C2 (OSRAM)
WO (1) WO2003029232A1 (OSRAM)
ZA (1) ZA200401583B (OSRAM)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
ATE406894T1 (de) * 2003-04-04 2008-09-15 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
CN1767829A (zh) * 2003-04-04 2006-05-03 H.隆德贝克有限公司 作为5－羟色胺再摄取抑制剂的4－(2－苯氧基苯基)－哌啶或－1,2,3,6－四氢吡啶衍生物
AU2004226837A1 (en) * 2003-04-04 2004-10-14 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
ZA200507181B (en) * 2003-04-04 2007-03-28 Lundbeck & Co As 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
JP4090491B2 (ja) 2003-12-23 2008-05-28 ハー・ルンドベック・アクチエゼルスカベット ２−（１ｈ−インドリルスルファニル）−ベンジルアミン誘導体
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
EP1851207B1 (en) * 2005-02-10 2009-07-01 Neurosearch A/S Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
SI2044043T2 (sl) 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
ATE508115T1 (de) * 2006-06-16 2011-05-15 Lundbeck & Co As H Kristalline formen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin mit kombinierter serotonin- und norepinephrinwiederaufnahmehemmung zur behandlung neuropathischer schmerzen
CN101472891B (zh) * 2006-06-16 2013-08-21 H.隆德贝克有限公司 有神经病痛治疗用血清素和去甲肾上腺素再摄取综合抑制作用的4-[2-(4-甲基苯硫基)苯基]哌啶的结晶形式
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
SI2167085T1 (sl) 2007-06-15 2014-05-30 H. Lundbeck A/S 4-(2-(4-metilfenilsulfanil)fenil)piperidin za zdravljenje sindroma razdraĺ˝ljivega äśrevesja (ibs)
TW200932233A (en) 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
CA2742105C (en) * 2008-11-14 2016-09-13 Theravance, Inc. 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
ES2512719T3 (es) * 2009-04-24 2014-10-24 H. Lundbeck A/S Formulaciones líquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil)fenil]piperazina
NZ598083A (en) 2009-08-24 2013-08-30 Lundbeck & Co As H New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
CA2779108C (en) * 2009-10-30 2018-01-02 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
US8778949B2 (en) 2010-01-11 2014-07-15 Theravance Biopharma R&D Ip, Llc 1-(2-phenoxymethylphenyl)piperazine compounds
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
EP2564837B1 (en) 2010-04-30 2019-01-30 Takeda Pharmaceutical Company Limited Enteric tablet
CA2797812C (en) 2010-04-30 2018-02-20 Takeda Pharmaceutical Company Limited Enteric tablet
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
LT2720989T (lt) 2011-06-20 2016-11-25 H. Lundbeck A/S Deuterinti 1-piperazin-3-fenilindanai, skirti šizofrenijos gydymui
CA2855640C (en) 2011-11-14 2020-03-10 The General Hospital Corporation Assays and methods for selecting a treatment regimen for a subject with depression
LT2800746T (lt) * 2012-01-03 2019-06-10 H. Lundbeck A/S 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazino gavimo būdas
US9499504B2 (en) 2012-09-19 2016-11-22 Sandoz Ag Crystalline form of vortioxetine hydrobromide
HRP20180333T1 (hr) 2012-12-13 2018-04-06 H. Lundbeck A/S Pripravci koji sadrže vortioksetin i donepezil
UA116236C2 (uk) * 2013-02-22 2018-02-26 Х. Луннбек А/С Спосіб одержання вортіоксетину
TR201906691T4 (tr) 2013-04-04 2019-05-21 Lek Pharmaceuticals 1-(2-((2,4-dimetilfenil)tiyo)fenil)piperazinin sentezine yönelik yeni proses.
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
WO2015044963A1 (en) 2013-09-30 2015-04-02 Cadila Healthcare Limited An amorphous vortioxetine and salts thereof
EP2878596A1 (en) * 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)lithium intermediates
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
JP6448645B2 (ja) 2013-12-20 2019-01-09 ハー・ルンドベック・アクチエゼルスカベット メランコリアの特徴を伴う抑うつ障害を処置するための、カッパ−活性を伴うオピオイド受容体拮抗薬およびボルチオキセチンの使用
EP2894154A1 (en) * 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2-(piperazine-1-yl)phenyl)aniline intermediates
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
EP3099669A1 (en) 2014-01-31 2016-12-07 Egis Gyógyszergyár Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (en) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthesis of vortioxetine via (2,4-dimethylphenyl)(2-iodophenyl)sulfane intermediate
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
EP3023417B1 (en) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Process for the preparation of an antidepressant and the intermediates thereof
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016135636A1 (en) 2015-02-25 2016-09-01 Lupin Limited Process for the preparation of vortioxetine
US20180072690A1 (en) 2015-03-26 2018-03-15 Cipla Limited Methods for Making Serotonin Reuptake Inhibitors
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
CA2992161A1 (en) * 2015-07-17 2017-01-26 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US20180237386A1 (en) * 2015-08-19 2018-08-23 Amneal Pharmaceuticals Company Gmbh Process For Preparation Of Vortioxetine Hydrobromide
US20180303772A1 (en) * 2015-10-14 2018-10-25 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
MX2018015759A (es) 2016-07-01 2019-03-21 H Lundbeck As Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
MX386989B (es) * 2016-07-15 2025-03-19 Pasteur Institut Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.
EA201990362A1 (ru) * 2016-07-22 2019-07-31 Цзянсу Нхвалокан Фармасьютикал Рисерч Энд Дивелопмент Ко., Лтд. Аналог вортиоксетина и его применение и получение
WO2018042168A1 (en) 2016-08-29 2018-03-08 King, Lawrence Stable pharmaceutical composition of vortioxetine hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
WO2018154451A1 (en) * 2017-02-23 2018-08-30 Unichem Laboratories Ltd An improved process for preparation and purification of vortioxetine hydrobromide
EP3615518B1 (en) * 2017-04-25 2021-12-15 H. Lundbeck A/S Process for the manufacture of vortioxetine hbr alpha-form
EP3412661A1 (en) 2017-06-08 2018-12-12 Enantia, S.L. Cocrystals of vortioxetine hydrobromide and resorcinol
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
EP3810582B1 (en) 2018-06-20 2024-01-03 Vio Ag Pharmaceuticals S.A. A one-pot organo-pseudocatalytic c-h activation approach for the preparation of vortioxetine and vortioxetine intermediate
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
US12281088B2 (en) 2020-09-10 2025-04-22 Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd Process for the synthesis of vortioxetine
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine
WO2025132869A1 (en) 2023-12-21 2025-06-26 H. Lundbeck A/S Method for the preparation of vortioxetine pharmaceutical compositions with low amounts of nitrosamine impurities
CN120774863A (zh) * 2024-04-02 2025-10-14 王春刚 一种烷基二胺取代双芳杂环基硫醚类化合物及其制备和在制备治疗和/或预防肿瘤药物中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151752B1 (OSRAM) 1971-04-13 1973-11-19
CS151753B1 (OSRAM) 1971-04-13 1973-11-19
CS151755B1 (OSRAM) 1971-04-13 1973-11-19
CS151751B1 (OSRAM) 1971-04-13 1973-11-19
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) * 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
US4198419A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
ES2004809A6 (es) * 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
DE69634678T2 (de) 1995-01-23 2006-01-19 Daiichi Suntory Pharma Co., Ltd. Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
DE69828317T2 (de) * 1997-10-31 2005-05-25 Daiichi Suntory Pharma Co., Ltd. Verfahren zur Herstellung von N-((4-Phenyl)methylphenyl)piperazinen
CN1351588A (zh) 1999-04-02 2002-05-29 伊科斯公司 白细胞功能相关抗原与细胞间粘着分子结合的抑制剂及其用途
AU6621600A (en) 1999-08-04 2001-03-05 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
JP2003509294A (ja) * 1999-09-14 2003-03-11 ファーマコペイア インコーポレイテッド マルチチャネル分散ヘッドを含む物品
WO2001049681A1 (en) * 1999-12-30 2001-07-12 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
EA006071B1 (ru) * 1999-12-30 2005-08-25 Х.Лундбекк А/С Замещенные производные фенилпиперазина, их получение и применение
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
DE60205465T2 (de) * 2001-01-23 2006-04-20 Eli Lilly And Co., Indianapolis Piperazinderivate als agonisten des melanocortin-rezeptors
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
HUP0402320A2 (hu) * 2001-12-20 2005-03-29 H. Lundbeck A/S Ariloxifenil- és arilszulfanilfenil-piperazin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
ATE406894T1 (de) * 2003-04-04 2008-09-15 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidin-derivate als serotonin-wiederaufnahme-hemmer
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
SI2044043T2 (sl) * 2006-06-16 2021-04-30 H. Lundbeck A/S 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje

Also Published As

Publication number Publication date
CY1110064T1 (el) 2015-01-14
ES2298425T3 (es) 2008-05-16
RS52865B (sr) 2013-12-31
ZA200401583B (en) 2005-05-25
UA81749C2 (uk) 2008-02-11
BR122012023120B1 (pt) 2017-03-21
DE60225162D1 (de) 2008-04-03
CA2462110E (en) 2003-04-10
MEP6508A (xx) 2010-02-10
MXPA04002959A (es) 2004-07-05
KR100770194B1 (ko) 2007-10-25
NL300652I2 (OSRAM) 2016-01-18
IS7164A (is) 2004-02-26
BE2014C036I2 (OSRAM) 2021-11-22
LTC1436271I2 (lt) 2016-09-12
JP3955613B2 (ja) 2007-08-08
PL210551B1 (pl) 2012-02-29
RS20120158A2 (sr) 2012-10-31
CN1561336A (zh) 2005-01-05
MY140950A (en) 2010-02-12
FR14C0033I1 (OSRAM) 2014-06-13
CY1107924T1 (el) 2013-09-04
EP1749818B1 (en) 2009-09-02
US20050014740A1 (en) 2005-01-20
BR0212733B1 (pt) 2014-05-13
AU2002333220B2 (en) 2008-02-07
KR20040047886A (ko) 2004-06-05
DK1749818T3 (da) 2009-10-12
PL209253B1 (pl) 2011-08-31
ES2328725T3 (es) 2009-11-17
AU2002333220A2 (en) 2003-04-14
NO20041628L (no) 2004-04-21
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
AU2002333220C1 (en) 2023-10-05
AU2006215994A9 (en) 2006-10-05
NO332355B1 (no) 2012-09-03
US7144884B2 (en) 2006-12-05
KR20060118020A (ko) 2006-11-17
US7138407B2 (en) 2006-11-21
CO5580746A2 (es) 2005-11-30
LTPA2014013I1 (lt) 2014-04-25
WO2003029232A1 (en) 2003-04-10
KR100783346B1 (ko) 2007-12-07
HRP20040220A2 (en) 2005-02-28
EP1749818A2 (en) 2007-02-07
EP1436271B3 (en) 2022-04-20
US8110567B2 (en) 2012-02-07
EA200400498A1 (ru) 2004-08-26
NO2014011I1 (no) 2014-05-13
BR122012009534B8 (pt) 2019-01-29
EA007537B1 (ru) 2006-10-27
US20180127389A1 (en) 2018-05-10
ES2298425T7 (es) 2022-06-27
NL300652I1 (OSRAM) 2016-01-18
IL160655A0 (en) 2004-07-25
EP1436271A1 (en) 2004-07-14
AU2006215994B2 (en) 2008-11-13
US9708280B2 (en) 2017-07-18
HU228956B1 (en) 2013-07-29
RS27704A (sr) 2006-10-27
JP3955614B2 (ja) 2007-08-08
US9090575B2 (en) 2015-07-28
IS2732B (is) 2011-04-15
CY2014022I2 (el) 2015-12-09
NO2014011I2 (no) 2015-08-31
BR122012009534B1 (pt) 2018-02-27
ATE386730T1 (de) 2008-03-15
CA2462110C (en) 2010-05-11
DE60233608D1 (de) 2009-10-15
CN1319958C (zh) 2007-06-06
RS20120158A3 (en) 2013-10-31
DE60225162T2 (de) 2009-02-12
AR036659A1 (es) 2004-09-22
CY2014022I1 (el) 2015-12-09
US20120302553A1 (en) 2012-11-29
JP2005505585A (ja) 2005-02-24
US20060084662A1 (en) 2006-04-20
ATE441631T1 (de) 2009-09-15
US20160137620A1 (en) 2016-05-19
KR20070103515A (ko) 2007-10-23
DK1436271T3 (da) 2008-06-09
US20060089368A1 (en) 2006-04-27
CA2462110A1 (en) 2003-04-10
AR066460A2 (es) 2009-08-19
HK1072600A1 (zh) 2005-09-02
PL368442A1 (pl) 2005-03-21
NZ531556A (en) 2005-12-23
RS52326B (sr) 2012-12-31
HU230189B1 (hu) 2015-09-28
ME00039B (me) 2010-06-10
JP2007031447A (ja) 2007-02-08
PT1749818E (pt) 2009-10-06
AU2006215994A1 (en) 2006-10-05
NO326443B1 (no) 2008-12-08
IS2578B (is) 2010-02-15
US10844029B2 (en) 2020-11-24
LU92397I2 (fr) 2014-05-12
EA011096B1 (ru) 2008-12-30
KR100842702B1 (ko) 2008-07-01
HUP0402313A2 (hu) 2005-02-28
EP1749818A3 (en) 2008-04-02
NO20083446L (no) 2004-04-21
BRPI0212733B8 (pt) 2021-05-25
JP2007051149A (ja) 2007-03-01
JP3896116B2 (ja) 2007-03-22
US20070060574A1 (en) 2007-03-15
HUS1400012I1 (hu) 2020-12-28
PT1436271E (pt) 2008-04-10
US20110009423A1 (en) 2011-01-13
UA93857C2 (uk) 2011-03-25
EA007537B3 (ru) 2015-02-27
AU2006215994A2 (en) 2006-10-05
US7148238B2 (en) 2006-12-12
BR122012023120B8 (pt) 2022-01-18
SI1436271T1 (sl) 2008-06-30
HUP0402313A3 (en) 2010-03-29
EG25095A (en) 2011-08-17
US20140163043A1 (en) 2014-06-12
EA200601269A1 (ru) 2007-02-27
US7683053B2 (en) 2010-03-23
US20210276966A1 (en) 2021-09-09
EP1436271B1 (en) 2008-02-20
BR0212733A (pt) 2004-11-16
IS8806A (is) 2009-03-10
US8476279B2 (en) 2013-07-02
DK1436271T6 (da) 2022-06-27

Similar Documents

Publication Publication Date Title
FR14C0033I2 (fr) Derives de phenyl-piperazine en tant qu'inhibiteurs du recaptage de la serotonine
NO20034307L (no) Cyklopropylindol-derivater som selektive serotonin- gjenopptaksinhibitorer
FR15C0086I2 (fr) Derives d'hydroxamate en tant qu'inhibiteurs de desacetylase
FR18C1024I2 (fr) Derives d'heterocyclocarboxamide
FR15C0068I2 (fr) Derives de diamine
NO20043022L (no) 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
MA26344A1 (fr) Derives 1,8-naphtyridine utilises comme antidiabetiques
EP1415974A4 (en) PROCESS FOR THE PREPARATION OF FLUOROUS NORBORENE DERIVATIVES
NO20030842L (no) Fenoksybenzylaminderivater som selektive serotonin- gjenopptaksinhibitorer
NO20034525D0 (no) Fenyl heterocyklyleterderivater som serotonin re- opptaksinhibitorer
DZ3489A1 (fr) Procede de preparation de mesylates de derives de piperazine
FR2833596B1 (fr) Procede de preparation de derives d'echinocandine
EP1829864A4 (en) ISOCHINOLINE DERIVATIVES AS CALPAININHIBITORS
EP1192128A4 (en) THIOLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS
ITMI20011718A0 (it) Processo per la preparazione del sale sodico dell'acido-6(d-(-)-alpha-(4-etil-2,3-diosso-1-piperazinocarbonilammino)fenilacetammido)penicill
DE60321724D1 (de) 1,2-diaza-dibenzoazulene als inhibitoren der produfür deren herstellung
FR2829136B1 (fr) Derives lipidiques d'aminoglycosides
NO20040913L (no) Nye 2,4-diaminotiazolderivater
HK1060563A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors